The FDA, on 16 November 2018, granted approval to BV with chemotherapy for newly diagnosed systemic anaplastic large cell lymphoma and other CD30-expressing peripheral T-cell lymphomas (PTCL) [60]. This evidence concerns the gene TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified.